MedTrace Logo

A Follow-up Study on Safety and Tolerability of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease

NCT01807338 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2014-10-09

No results posted yet for this study

Summary

The purpose of this study is to document the long-term safety and tolerability after intracerebroventricular (ICV) administration of sNN0031 (PDGF-BB) in patients who participated in study sNN0031-001

Conditions

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • TFS Trial Form Support

    collaborator INDUSTRY

  • Newron Sweden AB

    lead INDUSTRY

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01807338 on ClinicalTrials.gov